Abstract:Background B-cell maturation antigen (BCMA) is a potential therapeutic target in treatment of patients with MM. BCMA is widely expressed at the surface of myeloma cells and induces proliferative signals. BCMA-directed BCMA antibody conjugated with toxin has recently demonstrated outstanding anti-tumor responses and acceptable tolerability in MM treatment, allowing patients to achieve deeper responses with minimally added toxicity. Methods We used ELISA and FACS to verify AP163 can be combined with CD3/BCMA protein on the cell surface. We used the reporter gene method to verify that it induced T cell activation and target cell killing. In vivo, efficacy was studied in NCI-H929 and Raji xenograft models in female NPG mice. NPG mice were injected subcutaneously into the right dorsal flank with NCI-H929/Raji cells and human PBMC. Then the mice were treated with AP163 and tumor volume was measured twice/week. Cynomolgus monkeys were mainly used for toxicity testing. Intravenous administration is consistent with clinical administration. Its main toxicological target is the increase of cytokines and a series of adverse reactions. Results we constructed AP163 which binds to BCMA-expressing cell lines. AP163 induced both types of cell crosslinking, followed by T cell activation, cytokine production, proliferation and redirected target cell killing, with EC50 values in the picomolar range. The affinities of AP163 with human and cynomolgus CD3 are comparable. In vitro, AP163 only induced minimal cytokine release in the presence of BCMA target. When administered to mice bearing human MM xenografts and human T cells, AP163 eradicated subcutaneous tumors in two xenograft models tested and significantly delayed tumor growth at doses as low as 0.04mg/kg. AP163 displayed a 9-h half-life in cynomolgus and was well tolerated in non-human primates, even at high doses up to 5 mg/kg. Conclusions AP163 clears tumor cells in a BCMA+ and T-cell dependent manner in vitro and in vivo. Our preclinical data suggest that AP163 induces less cytokine secretion than a conventional bispecific in vitro, with reduction of tumor cell in vivo. AP163 is highly efficacious, safe and convenient for the treatment of patients with MM. Legal entity responsible for the study National Engineering Laboratory of High Level Expression In Mammalian Cells. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy

BCL2-BH4 Antagonist BDA-366 Suppresses Human Myeloma Growth

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting

4-Chlorobenzoyl Berbamine, a Novel Berbamine Derivative, Induces Apoptosis in Multiple Myeloma Cells Through the IL-6 Signal Transduction Pathway and Increases FOXO3a-Bim Expression.

4-Chlorbenzoyl Berbamine, a Novel Derivative of the Natural Product Berbamine, Potently Inhibits the Growth of Human Myeloma Cells by Modulating the NF-κB and JNK Signalling Pathways

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.

A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma

Abstract 2922: Development of Bcl2 BH4 Antagonist for Cancer Therapy

HDAC Inhibitor and BCL2 Selective Inhibitor Synergistically Exert Cytotoxicity on Human Myeloma Cells by Upregulating BIM Expression

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

A novel phosphoramide compound, DCZ0847, displays <i>in vitro</i> and <i>in vivo</i> anti-myeloma activity, alone or in combination with bortezomib

BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo

A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib

A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway

A Novel Bispecific BCMAxCD3 T Cell-Engaging Antibody That Treat Multiple Myeloma (MM) with Minimal Cytokine Secretion

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway

IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma

Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-KB signaling<i> in</i><i> vivo</i>

Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain

BRD4 Inhibitor Nitroxoline Enhances the Sensitivity of Multiple Myeloma Cells to Bortezomib in Vitro and in Vivo by Promoting Mitochondrial Pathway-Mediated Cell Apoptosis.

Preclinical Evaluation of STI-8811, a Novel Antibody Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma